<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04241393</url>
  </required_header>
  <id_info>
    <org_study_id>CVL-751-HV-001</org_study_id>
    <nct_id>NCT04241393</nct_id>
  </id_info>
  <brief_title>An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy Subjects</brief_title>
  <official_title>An Open-label Trial to Evaluate the Absorption, Metabolism, and Excretion of a Single Dose of [14C]-Tavapadon in Healthy Adult Male Subjects at Steady State</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cerevel Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cerevel Therapeutics, LLC</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine the absorption, metabolism, and excretion (AME) of&#xD;
      [14C] tavapadon.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 4, 2020</start_date>
  <completion_date type="Actual">November 8, 2020</completion_date>
  <primary_completion_date type="Actual">November 8, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of [14C]-Tavapadon and Metabolites: Area under the radioactivity time curve from zero to infinity (AUCinf) for Tavapadon and Metabolites (PF-06752844), in plasma and whole blood</measure>
    <time_frame>Day 16 up to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of [14C]-Tavapadon and Metabolites: Area under the radioactivity time curve from time 0 to last quantifiable concentration (AUClast) for Tavapadon and Metabolites (PF-06752844), in plasma and whole blood</measure>
    <time_frame>Day 16 up to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of [14C]-Tavapadon and Metabolites: Peak radioactivity Cmax) for Tavapadon and Metabolites (PF-06752844), in plasma and whole blood</measure>
    <time_frame>Day 16 up to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of [14C]-Tavapadon and Metabolites: Time to last measurable radioactivity (Tlast) for Tavapadon and Metabolites (PF-06752844), in plasma and whole blood</measure>
    <time_frame>Day 16 up to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of [14C]-Tavapadon and Metabolites: Time to maximum radioactivity (Tmax) for Tavapadon and Metabolites (PF-06752844), in plasma and whole blood</measure>
    <time_frame>Day 16 up to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of [14C]-Tavapadon and Metabolites: elimination half-life (t½) for Tavapadon and Metabolites (PF-06752844), in plasma and whole blood</measure>
    <time_frame>Day 16 up to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of Tavapadon: Apparent total body clearance (CL/F) for Tavapadon</measure>
    <time_frame>Day 16 up to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of Tavapadon: Apparent volume of distribution (Vz/F) for Tavapadon</measure>
    <time_frame>Day 16 up to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of Plasma AUCinf for Tavapadon to whole blood total Radioactivity AUCinf</measure>
    <time_frame>Day 16 up to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of Plasma AUCinf for Metabolites (PF-06752844) to whole blood total Radioactivity AUCinf</measure>
    <time_frame>Day 16 up to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of plasma AUCinf for Metabolites (PF-06752844) to plasma AUCinf for Tavapadon</measure>
    <time_frame>Day 16 up to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of whole blood AUCinf for Tavapadon (and metabolites, measured as total radioactivity) to plasma AUCinf for Tavapadon (and metabolites, measured as total radioactivity)</measure>
    <time_frame>Day 16 up to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of [14C]-Tavapadon: Total radioactivity in urine at different intervals</measure>
    <time_frame>Day 16 up to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of [14C]-Tavapadon: Cumulative radioactivity excreted in urine (Cumulative Aeu)</measure>
    <time_frame>Day 16 up to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of [14C]-Tavapadon: Fraction of the dose administered excreted in urine (Feu) for total radioactivity at different intervals</measure>
    <time_frame>Day 16 up to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of [14C]-Tavapadon: Cumulative fraction of the dose administered excreted in urine (Cumulative Feu) for total radioactivity in urine</measure>
    <time_frame>Day 16 up to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of [14C]-Tavapadon: Amount eliminated in feces (Aef) for total radioactivity in feces at different intervals</measure>
    <time_frame>Day 16 up to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of [14C]-Tavapadon: Cumulative amount excreted in feces (Cumulative Aef) for total radioactivity in feces</measure>
    <time_frame>Day 16 up to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of [14C]-Tavapadon: Fraction of the dose administered excreted in feces (Fef) for total radioactivity in feces at different intervals</measure>
    <time_frame>Day 16 up to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of [14C]-Tavapadon: Cumulative Fraction of the dose administered excreted in feces (Cumulative Fef) for total radioactivity in feces</measure>
    <time_frame>Day 16 up to Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects with reported Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with Clinically significant changes in Electrocardiogram measures (PR,RR,QT and QTcF)</measure>
    <time_frame>Up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with Clinically meaningful changes in Vital signs (Systolic and Diastolic blood pressures, heart rate, respiratory rate and body temperature)</measure>
    <time_frame>Up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically significant changes in laboratory measures</measure>
    <time_frame>Up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of the Columbia-Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>At Baseline and up to Day 28</time_frame>
    <description>The C-SSRS rates an individual's degree of suicidal ideation (SI) on a scale, ranging from &quot;wish to be dead&quot; to &quot;active suicidal ideation with specific plan and intent.&quot; The scale identifies SI severity and intensity, which may be indicative of an individual's intent to commit suicide. C-SSRS SI severity subscale ranges from 0 (no SI) to 5 (active SI with plan and intent).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Tavapadon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tavapadon tablet</intervention_name>
    <description>Participants will receive multiple dose titration of Tavapadon (0.25 mg once daily [QD] on Days 1 to 3, 0.5 mg QD on Days 4 to 6, 1.0 mg QD on Days 7 to 9, 1.5 mg QD on Days 10 to 12, and 2.5 mg QD on Days 13 to 15)</description>
    <arm_group_label>Tavapadon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tavapadon [14C] suspension</intervention_name>
    <description>Following 15-Day multiple dose titration of Tavapadon, participants will receive a single oral dose of Tavapadon 2.5 mg containing approximately 100 μCi of [14C] Tavapadon on Day 16</description>
    <arm_group_label>Tavapadon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male subjects, ages 18 to 55 years, inclusive, at the time of signing the informed&#xD;
             consent form (ICF).&#xD;
&#xD;
          2. Body mass index (BMI) of 18.0 to 32.0 kg/m2 and a total body weight &gt; 50 kg (110 lbs).&#xD;
&#xD;
          3. In good health, determined by no clinically significant findings from medical history,&#xD;
             physical examination, 12-lead electrocardiogram (ECG), vital signs measurements, and&#xD;
             clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia [eg,&#xD;
             Gilbert's syndrome] is not acceptable) at Screening or Check-in as assessed by the&#xD;
             investigator (or designee).&#xD;
&#xD;
          4. Male subjects with a pregnant or a nonpregnant partner of childbearing potential must&#xD;
             agree to use an acceptable or a highly effective method of contraception from signing&#xD;
             of informed consent during the trial, and for 7 days following the last dose of study&#xD;
             drug.&#xD;
&#xD;
          5. Capable of giving signed informed consent which includes compliance with the&#xD;
             requirements and restrictions listed in the ICF and in the protocol.&#xD;
&#xD;
          6. Ability, in the opinion of the investigator, to understand the nature of the trial and&#xD;
             comply with protocol requirements, including the prescribed dosage regimens, scheduled&#xD;
             visits, laboratory tests, and other trial procedures.&#xD;
&#xD;
          7. Capable of consuming the standard diet.&#xD;
&#xD;
          8. History of a minimum of 1 bowel movement per day.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Medical History and Concurrent Diseases&#xD;
&#xD;
          1. Has a history of psychotic symptoms requiring treatment with an antipsychotic&#xD;
             medication within the 12 months prior to signing ICF.&#xD;
&#xD;
          2. Subjects with epilepsy, or history of epilepsy, or conditions that lower seizure&#xD;
             threshold, seizures of any etiology (including substance or drug withdrawal), or who&#xD;
             have increased risk of seizures as evidenced by history of electroencephalogram with&#xD;
             epileptiform activity. Subjects with a history of febrile seizures and/or history of&#xD;
             head trauma with loss of consciousness requiring hospitalization overnight will be&#xD;
             excluded as well.&#xD;
&#xD;
          3. Subjects with a current history of significant cardiovascular, pulmonary,&#xD;
             gastrointestinal, renal, hepatic, metabolic, hematological, immunological, or&#xD;
             neurological disease that, in the opinion of the investigator or medical monitor,&#xD;
             could compromise either subject safety or the results of the trial.&#xD;
&#xD;
             Medical conditions that are minor or well controlled may be considered acceptable if&#xD;
             the condition does not expose the subject to an undue risk of a significant AE or&#xD;
             interfere with the assessments of safety during the course of the trial. The medical&#xD;
             monitor should be contacted in any instance where the investigator is uncertain&#xD;
             regarding the stability of a subject's medical conditions(s) and the potential impact&#xD;
             of the condition(s) on trial participation.&#xD;
&#xD;
          4. Any condition possibly affecting drug absorption including history of stomach or&#xD;
             intestinal surgery or resection that would potentially alter absorption and/or&#xD;
             excretion of orally administered drugs (uncomplicated appendectomy and hernia repair&#xD;
             will be allowed; cholecystectomy and bariatric weight loss surgeries will not be&#xD;
             allowed).&#xD;
&#xD;
          5. History of substance or alcohol-use disorder (excluding nicotine; Diagnostic and&#xD;
             Statistical Manual of Mental Disorders, 5th edition criteria) within 2 years prior to&#xD;
             signing the ICF.&#xD;
&#xD;
          6. History of regular alcohol consumption exceeding 14 drinks/week [1 drink = 5 ounces&#xD;
             (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor]&#xD;
             within 6 months prior to signing ICF.&#xD;
&#xD;
          7. Use of tobacco- or nicotine-containing products within 3 months prior to Check-in.&#xD;
&#xD;
          8. Subjects who answer &quot;yes&quot; on the Columbia-Suicide Severity Rating Scale (C-SSRS)&#xD;
             Suicidal Ideation Item 4 or Item 5 (Active Suicidal Ideation with Some Intent to Act,&#xD;
             Without Specific Plan, or Active Suicidal Ideation with Specific Plan and Intent) and&#xD;
             whose most recent episode meeting the criteria for C-SSRS Item 4 or Item 5 occurred&#xD;
             within the last 6 months, OR&#xD;
&#xD;
             Subjects who answer &quot;yes&quot; on any of the 5 C-SSRS Suicidal Behavior Items (actual&#xD;
             attempt, interrupted attempt, aborted attempt, preparatory acts, or behavior) and&#xD;
             whose most recent episode meeting the criteria for any of these 5 C-SSRS Suicidal&#xD;
             Behavior Items occurred within the last 2 years, OR&#xD;
&#xD;
             Subjects who, in the opinion of the investigator, present a serious risk of suicide.&#xD;
&#xD;
          9. Subjects who have attempted suicide in the past.&#xD;
&#xD;
             - Physical Examination and Clinical Laboratory Results&#xD;
&#xD;
         10. Positive hepatitis panel (hepatitis B surface antigen and hepatitis C virus antibody)&#xD;
             and/or positive human immunodeficiency virus test (HIV-1 and HIV-2 antibody) at&#xD;
             Screening.&#xD;
&#xD;
         11. Positive urine drug screen (with cotinine) or positive alcohol breathalyzer at&#xD;
             Screening and Check-in. Subjects with a positive drug screen for illicit drugs or&#xD;
             cotinine are excluded and may not be retested or rescreened. Subjects with a positive&#xD;
             urine drug screen resulting from use of marijuana (any cannabinoids), prescription&#xD;
             medications, over-the-counter medications, or products that, in the investigator's&#xD;
             documented opinion, do not signal a clinical condition that would impact the safety of&#xD;
             the subject or interpretation of the trial results may continue evaluation for the&#xD;
             trial following consultation and explicit approval by the medical monitor.&#xD;
&#xD;
         12. Subjects with a 12-lead ECG demonstrating the following:&#xD;
&#xD;
             • QT interval corrected for heart rate using Fridericia's formula &gt;450 msec (average&#xD;
             of 3 ECGs obtained at the Screening Visit).&#xD;
&#xD;
         13. Subjects with any of the following abnormalities in clinical laboratory tests at the&#xD;
             Screening Visit, confirmed by a single repeat measurement, if deemed necessary, and at&#xD;
             the discretion of the investigator:&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥2 × upper&#xD;
                  limit of normal (ULN)&#xD;
&#xD;
               -  Total bilirubin ≥1.5 × ULN.&#xD;
&#xD;
         14. Subjects with other abnormal laboratory test results, vital sign results, or ECG&#xD;
             findings unless, based on the investigator's judgment, the findings are not medically&#xD;
             significant and would not impact the safety of the subjects or the interpretation of&#xD;
             the trial results. The medical monitor should be contacted to discuss individual&#xD;
             cases, as needed.&#xD;
&#xD;
             Tests with exclusionary results should be repeated to ensure reproducibility of the&#xD;
             abnormality before excluding a subject based on criteria provided in the protocol. For&#xD;
             ECGs, 3 consecutive recordings are required and if 2 of the 3 remain exclusionary,&#xD;
             then the subject is not eligible for the trial.&#xD;
&#xD;
             - Disallowed Prior and Concomitant Medications&#xD;
&#xD;
         15. Subjects taking other prohibited medication or who would be likely to require&#xD;
             prohibited concomitant therapy during the trial.&#xD;
&#xD;
             - Other&#xD;
&#xD;
         16. Subjects with difficulty swallowing.&#xD;
&#xD;
         17. Subjects who are known to be allergic or hypersensitive to the IMP or any of its&#xD;
             components.&#xD;
&#xD;
         18. Subjects who are known to be allergic or hypersensitive to contents of the standard&#xD;
             diet.&#xD;
&#xD;
         19. Subjects who have participated in any clinical trial involving administration of an&#xD;
             investigational drug (new chemical entity) in the past 30 days or 5 half-lives (if&#xD;
             known) prior to dosing.&#xD;
&#xD;
         20. Receipt of blood products within 2 months prior to Check-in.&#xD;
&#xD;
         21. Donation of blood from 56 days prior to Screening, plasma from 2 weeks prior to&#xD;
             Screening, or platelets from 6 weeks prior to Screening.&#xD;
&#xD;
         22. Poor peripheral venous access.&#xD;
&#xD;
         23. Subjects with exposure to significant diagnostic or therapeutic radiation (eg, serial&#xD;
             X-ray, computed tomography scan, barium meal) or current employment in a job requiring&#xD;
             radiation exposure monitoring within 12 months prior to Check-in.&#xD;
&#xD;
         24. Subjects who have participated in a radiolabeled drug trial where exposures are known&#xD;
             to the investigator within the previous 4 months prior to admission to the clinic for&#xD;
             this trial or participated in a radiolabeled drug trial where exposures are not known&#xD;
             to the investigator within the previous 6 months prior to admission to the clinic for&#xD;
             this trial. The total 12-month exposure from this trial and a maximum of 2 other&#xD;
             previous radiolabeled trials within 4 to 12 months prior to this trial will be within&#xD;
             the CFR recommended levels considered safe, per US Title 21 CFR 361.1: less than 5,000&#xD;
             mrem whole body annual exposure with consideration given to the half-lives of the&#xD;
             previous radiolabeled trial drugs received.&#xD;
&#xD;
         25. Any subject who, in the opinion of the sponsor, investigator, or medical monitor,&#xD;
             should not participate in the trial.&#xD;
&#xD;
         26. Subjects who are investigational site staff members directly involved in the conduct&#xD;
             of the trial and their family members, site staff members otherwise supervised by the&#xD;
             investigator.&#xD;
&#xD;
         27. Unwilling or unable to comply with the lifestyle modifications described in this&#xD;
             protocol.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Leoni, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cerevel Therapeutics, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit, Inc.</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>January 22, 2020</study_first_submitted>
  <study_first_submitted_qc>January 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

